Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Venus Remedies Limited ( (IN:VENUSREM) ) has shared an update.
Venus Remedies Limited has successfully completed all commercial milestones under its 2019 agreement with Cipla Ltd, receiving a final payment of Rs. 11 crore for its AMR-focused anti-infective product. This milestone underscores the product’s clinical impact, having treated over one million patients without serious adverse events, and highlights Venus Remedies’ commitment to innovation in addressing antimicrobial resistance. The company plans to continue prioritizing AMR with a pipeline of promising antibacterial candidates and ongoing initiatives in surveillance and stewardship.
More about Venus Remedies Limited
Venus Remedies Limited operates in the pharmaceutical industry, focusing on the development and distribution of anti-infective products. The company, through its Venus Medicine Research Centre, targets multidrug-resistant infections and has a strong market presence in India.
Average Trading Volume: 7,868
Technical Sentiment Signal: Buy
Current Market Cap: 9.96B INR
See more insights into VENUSREM stock on TipRanks’ Stock Analysis page.